Microbial Biotechnology,
Год журнала:
2023,
Номер
16(10), С. 1985 - 2006
Опубликована: Авг. 21, 2023
Clostridioides
difficile
infection
(CDI)
as
of
recent
has
become
a
great
concern
to
the
impact
on
human
health
due
its
high
hazardous
risk
and
rate
recurrence.
Live
bacterial
therapeutics
is
promising
method
treat
or
prevent
CDI.
Here,
synthetic
microbial
consortia
(SMC)
B10
was
constructed
using
probiotic
strains
with
antibacterial
anti-quorum
sensing
activities,
therapeutic
effect
SMC
against
C.
evaluated
in
vitro.
Compared
model
group,
treatment
significantly
increased
survival
rate.
The
clinical
signs
mice
were
ameliorated,
especially
cecum
injury,
while
secretion
pro-inflammatory
associated
cytokines
such
IL-1α,
IL-6,
IL-17A
TNF-α
reduced,
expression
TLR4
inhibited,
which
alleviated
inflammatory
response,
tight
junction
protein
Claudin-1
increased,
ultimately
promoting
recovery
host
health.
restored
gut
microbiota
dysbiosis
led
healthy
intestinal
structure,
improved
alpha
diversity,
suppressing
potentially
harmful
bacteria
restoring
other
core
species.
In
conclusion,
can
effectively
CDI
through
modulate
attenuate
response.
Food & Function,
Год журнала:
2023,
Номер
14(23), С. 10401 - 10417
Опубликована: Янв. 1, 2023
Gut
microbiota
are
closely
related
to
lipopolysaccharide
(LPS)-induced
acute
lung
injury
(ALI).
Akkermansia
muciniphila
(A.
muciniphila)
maintains
the
intestinal
barrier
function
and
regulates
balance
of
reduced
glutathione/oxidized
glutathione.
However,
it
may
be
useful
as
a
treatment
strategy
for
LPS-induced
injury.
Our
study
aimed
explore
whether
A.
could
improve
by
affecting
gut
microbiota.
The
administration
effectively
attenuated
tissue
damage
significantly
decreased
oxidative
stress
inflammatory
reaction
induced
LPS,
with
lower
levels
myeloperoxidase
(MDA),
enhanced
superoxide
dismutase
(SOD)
activity,
pro-inflammatory
cytokine
levels,
macrophage
neutrophil
infiltration.
Moreover,
maintained
function,
reshaped
disordered
microbial
community,
promoted
secretion
short-chain
fatty
acids
(SCFAs).
downregulated
expression
TLR2,
MyD88
NF-kappa
B
(P
<
0.05).
Butyrate
supplementation
demonstrated
significant
improvement
in
response
0.05)
mitigation
histopathological
mice
ALI,
thereby
restoring
butyric
acid
concentration.
In
conclusion,
our
findings
indicate
that
inhibits
accumulation
cytokines
attenuates
activation
TLR2/Myd88/NF-κB
pathway
due
exerting
anti-inflammatory
effects
through
butyrate.
This
provides
an
experimental
foundation
potential
application
butyrate
prevention
ALI.
Frontiers in Microbiology,
Год журнала:
2024,
Номер
15
Опубликована: Фев. 6, 2024
Akkermansia
muciniphila
is
a
gram-negative
bacterium
that
colonizes
the
human
gut,
making
up
3–5%
of
microbiome.
A.
promising
next-generation
probiotic
with
clinical
application
prospects.
Emerging
studies
have
reported
various
beneficial
effects
including
anti-cancer,
delaying
aging,
reducing
inflammation,
improving
immune
function,
regulating
nervous
system
whereas
knowledge
on
its
roles
and
mechanism
in
infectious
disease
currently
unclear.
In
this
review,
we
summarized
basic
characteristics,
genome
phenotype
diversity,
influence
derived
components
diseases,
such
as
sepsis,
virus
infection,
enteric
periodontitis
foodborne
pathogen
induced
infections.
We
also
provided
updates
mechanisms
how
protects
intestinal
barrier
integrity
modulate
host
response.
summary,
believe
therapeutic
may
be
applied
for
treatment
variety
diseases.
Abstract
Background
Fecal
microbiota
transplantation
(FMT)
and
fecal
virome
(FVT,
sterile
filtrated
donor
feces)
have
been
effective
in
treating
recurrent
Clostridioides
difficile
infections,
possibly
through
bacteriophage-mediated
modulation
of
the
gut
microbiome.
However,
challenges
like
variability,
costly
screening,
coupled
with
concerns
over
pathogen
transfer
(incl.
eukaryotic
viruses)
FMT
or
FVT
hinder
their
wider
clinical
application
less
acute
diseases.
Methods
To
overcome
these
challenges,
we
developed
methods
to
broaden
FVT’s
while
maintaining
efficacy
increasing
safety.
Specifically,
employed
following
approaches:
(1)
chemostat-fermentation
reproduce
bacteriophage
component
remove
viruses
(FVT-ChP),
(2)
solvent-detergent
treatment
inactivate
enveloped
(FVT-SDT),
(3)
pyronin-Y
inhibit
RNA
virus
replication
(FVT-PyT).
We
assessed
processed
FVTs
a
C.
infection
mouse
model
compared
them
untreated
(FVT-UnT),
FMT,
saline.
Results
FVT-SDT,
FVT-UnT,
FVT-ChP
reduced
incidence
mice
reaching
humane
endpoint
(0/8,
2/7,
3/8,
respectively)
FVT-PyT,
saline
(5/8,
7/8,
5/7,
significantly
load
colonizing
cells
associated
toxin
A/B
levels.
There
was
potential
elimination
colonization,
seven
out
eight
treated
FVT-SDT
testing
negative
qPCR.
In
contrast,
all
other
treatments
exhibited
continued
presence
.
Moreover,
results
were
supported
by
changes
microbiome
profiles,
cecal
cytokine
levels,
histopathological
findings.
Assessment
viral
engraftment
FMT/FVT
host-phage
correlations
analysis
suggested
that
phages
likely
an
important
contributing
factor
efficacy.
Conclusions
This
proof-of-concept
study
shows
specific
modifications
hold
promise
addressing
related
variability
risks.
Two
strategies
lead
limiting
colonization
mice,
solvent/detergent
chemostat
propagation
emerging
as
promising
approaches.
Biomedicine & Pharmacotherapy,
Год журнала:
2024,
Номер
173, С. 116416 - 116416
Опубликована: Март 11, 2024
Colorectal
cancer
(CRC)
is
the
second
most
cancer-related
death
worldwide.
In
recent
years,
probiotics
have
been
used
to
reduce
potential
risks
of
CRC
and
tumors
with
various
mechanisms.
Different
bacteria
suggested
play
different
roles
in
progression,
prevention,
or
treatment
CRC.
Akkermansia
muciniphila
considered
a
next-generation
probiotic
for
preventing
treating
some
diseases.
Therefore,
this
review
article,
we
aimed
describe
discuss
mechanisms
A.
as
an
intestinal
microbiota
Some
studies
that
abundance
was
higher
increased
patients
compared
healthy
individuals.
However,
decreased
associated
severe
symptoms
CRC,
indicating
did
not
role
development
addition,
administration
elevates
gene
expression
proliferation-associated
molecules
such
S100A9,
Dbf4,
Snrpd1,
markers
cell
proliferation.
other
inflammation
tumorigenesis
intestine
might
promoted
by
muciniphila.
Overall,
inhibition
still
unclear
controversial.
Various
methods
bacterial
supplementation,
viability,
number,
abundance,
could
all
influence
colonization
effect
progression.
mucinipila
has
revealed
modulate
therapeutic
immune
checkpoint
inhibitors.
Preliminary
human
data
propose
oral
consumption
safe,
but
its
efficacy
needs
be
confirmed
more
clinical
studies.
Nutrients,
Год журнала:
2025,
Номер
17(3), С. 562 - 562
Опубликована: Янв. 31, 2025
Akkermansia
muciniphila
is
a
bacterium
commonly
found
in
the
human
gastrointestinal
tract
that
has
received
considerable
interest
as
potential
probiotic
for
improvement
of
gut
health
and
overall
metabolic
function.
A.
enriched
mucus
layer
intestinal
lining,
where
it
degrades
mucin
plays
significant
role
barrier
maintenance
immune
regulation.
A
higher
abundance
been
observed
healthy
individuals
relative
to
those
with
disorders,
multiple
benefits,
including
improved
glucose
management,
reduced
body
fat,
inflammation
have
linked
muciniphila.
Current
research
on
primarily
relies
mouse
models,
limited
interventional
studies
available.
While
these
animal
offer
valuable
insights
into
roles
disease,
further
clinical
investigations
humans
are
needed
fully
understand
its
impact.
Here,
we
explore
current
scope
therapeutic
agent
improve
while
also
emphasizing
need
optimize
techniques
this
organism.
Journal of Agricultural and Food Chemistry,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 5, 2025
Takeda
G
protein-coupled
receptor
5
(TGR5),
also
known
as
bile
acid
1
(GPBAR1),
is
a
cell
surface
involved
in
key
physiological
processes,
including
glucose
homeostasis
and
energy
metabolism.
Recent
research
has
focused
on
the
role
of
TGR5
activation
preventing
or
treating
diabetes
while
highlighting
its
potential
impact
progression
diabetic
complications.
Functional
foods
edible
plants
have
emerged
valuable
sources
natural
compounds
that
can
activate
TGR5,
offering
therapeutic
benefits
for
management.
Despite
growing
interest,
studies
by
dietary
bioactive
remain
scattered.
This
Review
aims
to
provide
comprehensive
analysis
how
bioactives
act
agents
managing
It
explores
mechanisms
through
both
direct
agonistic
effects
indirect
pathways
via
modulation
gut
microbiota
